High-Throughput Profiling of Anti-Glycan Humoral Responses to SIV Vaccination and Challenge

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Campbell, Christopher T ^a   Llewellyn, Sean R ^a   Damberg, Thorsten ^b   Morgan, Ian L ^b   Robert Guroff, Marjorie ^b   Gildersleeve, Jeffrey C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCAN; GLYCAN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIMATE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; LENTIVIRUS INFECTIONS; MACACA MULATTA; MICROARRAY ANALYSIS; POLYSACCHARIDES; SAIDS VACCINES; VIRAL LOAD;

EID: 84884514406     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075302     Document Type: Article

References (74)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
3. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: e23521.
4. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
5. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
6. Doores KJ, Burton DR, (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510-10521.
7. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human Monoclonal Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp120 Glycoprotein of Human Immunodeficiency Virus Type 1. J Virol 70: 1100-1108.
8. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, et al. (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109: E3268-3277.
9. Kabanova A, Adamo R, Proietti D, Berti F, Tontini M, et al. (2010) Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconj J 27: 501-513.
10. Clark BE, Auyeung K, Fregolino E, Parrilli M, Lanzetta R, et al. (2012) A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. Chem Biol 19: 254-263.
11. Oyelaran O, Gildersleeve JC, (2009) Glycan arrays: recent advances and future challenges. Curr Opin Chem Biol 13: 406-413.
12. Rillahan CD, Paulson JC, (2011) Glycan microarrays for decoding the glycome. Annu Rev Biochem 80: 797-823.
13. Zhang YL, Campbell C, Li QA, Gildersleeve JC, (2010) Multidimensional glycan arrays for enhanced antibody profiling. Mol Biosyst 6: 1583-1591.
14. Manimala JC, Roach TA, Li Z, Gildersleeve JC, (2007) High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 17: 17C-23C.
15. Manimala JC, Roach TA, Li Z, Gildersleeve JC, (2006) High-throughput carbohydrate microarray analysis of 24 lectins. Angew Chem 45: 3607-3610.
16. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, et al. (2004) Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA 101: 17033-17038.
17. Rinaldi S, Brennan KM, Goodyear CS, O'Leary C, Schiavo G, et al. (2009) Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology 19: 789-796.
18. Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, et al. (2013) Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF. Clinical cancer research: an official journal of the American Association for Cancer Research 19: 1290-1299.
19. Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, et al. (2010) Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 17: 357-370.
20. Dunlop DC, Bonomelli C, Mansab F, Vasiljevic S, Doores KJ, et al. (2010) Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20: 812-823.
21. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, et al. (2008) An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J Virol 82: 6447-6457.
22. Lackner AA, Veazey RS, (2007) Current Concepts in AIDS Pathogenesis: Insights from the SIV/Macaque Model. Annu Rev Med 58: 461-476.
23. Baroncelli S, Negri DR, Michelini Z, Cara A, (2008) Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev Vaccines 7: 1419-1434.
24. Patterson LJ, Daltabuit-Test M, Xiao P, Zhao J, Hu W, et al. (2011) Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 411: 87-102.
25. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, et al. (2006) Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 353: 83-98.
26. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174: 2185-2189.
27. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, et al. (2004) Protection against Mucosal Simian Immunodeficiency Virus SIVmac251 Challenge by Using Replicating Adenovirus-SIV Multigene Vaccine Priming and Subunit Boosting. J Virol 78: 2212-2221.
28. Kalyanaraman VS, Rodriguez V, Veronese F, Rahman R, Lusso P, et al. (1990) Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 6: 371-380.
29. Zhao J, Pinczewski J, Gomez-Roman VR, Venzon D, Kalyanaraman VS, et al. (2003) Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 77: 8354-8365.
30. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, et al. (2002) Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10: S32-S37.
31. Harada S, Yoshiyama H, Yamamoto N, (1985) Effect of Heat and Fresh Human Serum on the Infectivity of Human T-Cell Lymphotropic Virus Type III Evaluated with New Bioassay System. J Clin Microbiol 22: 908-911.
32. Campbell CT, Zhang Y, Gildersleeve JC, (2010) Construction and use of glycan microarrays. Curr Protoc Chem Biol 2: 37-53.
33. Oyelaran O, McShane LM, Dodd L, Gildersleeve JC, (2009) Profiling human serum antibodies with a carbohydrate antigen microarray. J Proteome Res 8: 4301-4310.
34. Oyelaran O, Gildersleeve JC, (2010) Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray. Proteomics Clin Appl 4: 285-294.
35. Oyelaran O, Li Q, Farnsworth D, Gildersleeve JC, (2009) Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies. J Proteome Res 8: 3529-3538.
36. Shilova N, Navakouski M, Khasbiullina N, Blixt O, Bovin N, (2012) Printed glycan array: antibodies as probed in undiluted serum and effects of dilution. Glycoconj J 29: 87-91.
37. Kracun SK, Clo E, Clausen H, Levery SB, Jensen KJ, et al. (2010) Random glycopeptide bead libraries for seromic biomarker discovery. J Proteome Res 9: 6705-6714.
38. Blixt O, Clo E, Nudelman AS, Sorensen KK, Clausen T, et al. (2010) A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res 9: 5250-5261.
39. Schwarz M, Spector L, Gargir A, Shtevi A, Gortler M, et al. (2003) A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology 13: 749-754.
40. Bovin N, Obukhova P, Shilova N, Rapoport E, Popova I, et al. (2012) Repertoire of human natural anti-glycan immunoglobulins. Do we have auto-antibodies? Biochim Biophys Acta 1820: 1373-1382.
41. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, et al. (2009) Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 46: 3037-3049.
42. de Boer AR, Hokke CH, Deelder AM, Wuhrer M, (2008) Serum antibody screening by surface plasmon resonance using a natural glycan microarray. Glycoconj J 25: 75-84.
43. Tateno H, Mori A, Uchiyama N, Yabe R, Iwaki J, et al. (2008) Glycoconjugate microarray based on an evanescent-field fluorescence-assisted detection principle for investigation of glycan-binding proteins. Glycobiology 18: 789-798.
44. Pochechueva T, Chinarev A, Spengler M, Korchagina E, Heinzelmann-Schwarz V, et al. (2011) Multiplex suspension array for human anti-carbohydrate antibody profiling. The Analyst 136: 560-569.
45. Baader J, Klapproth H, Bednar S, Brandstetter T, Ruhe J, et al. (2011) Polysaccharide microarrays with a CMOS based signal detection unit. Biosens Bioelectron 26: 1839-1846.
46. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 102: 13372-13377.
47. Hansen JE, Nielsen C, Arendrup M, Olofsson S, Mathiesen L, et al. (1991) Broadly Neutralizing Antibodies Targeted to Mucin-Type Carbohydrate Epitopes of Human Immunodeficiency Virus. J Virol 65: 6461-6467.
48. Hansen JE, Clausen H, Hu SL, Nielsen JO, Olofsson S, (1992) An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch Virol 126: 11-20.
49. Mond JJ, Lees A, Snapper CM, (1995) T cell-independent antigens type 2. Annu Rev Immunol 13: 655-692.
50. Mond JJ, Vos Q, Lees A, Snapper CM, (1995) T cell independent antigens. Curr Opin Immunol 7: 349-354.
51. Hansen JE, Jansson B, Gram GJ, Claussen H, Nielsen JO, et al. (1996) Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop. Arch Virol 141: 291-300.
52. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW, (1994) Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol 68: 463-468.
53. Hansen JE, Jansson B, Gram GJ, Clausen H, Nielsen JO, et al. (1996) Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop. Arch Virol 141: 291-300.
54. Corbeau P, Pasquali JL, Devaux C, (1995) Jacalin, a lectin interacting with O-linked sugars and mediating protection of CD4+ cells against HIV-1, binds to the external envelope glycoprotein gp120. Immunol Lett 47: 141-143.
55. Stansell E, Canis K, Haslam SM, Dell A, Desrosiers RC, (2011) Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O-linked carbohydrate. J Virol 85: 582-595.
56. Borggren M, Repits J, Sterjovski J, Uchtenhagen H, Churchill MJ, et al. (2011) Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One 6: e20135.
57. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, et al. (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res 7: 1660-1674.
58. Go EP, Chang Q, Liao HX, Sutherland LL, Alam SM, et al. (2009) Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res 8: 4231-4242.
59. Go EP, Hewawasam G, Liao HX, Chen H, Ping LH, et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85: 8270-8284.
60. Tran NT, Taverna M, Merry AH, Chevalier M, Morgant G, et al. (2000) A sensitive mapping strategy for monitoring the reproducibility of glycan processing in an HIV vaccine, RGP-160, expressed in a mammalian cell line. Glycoconj J 17: 401-406.
61. Yu B, Morales JF, O'Rourke SM, Tatsuno GP, Berman PW, (2012) Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials. PLoS One 7: e43903.
62. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333: 1593-1602.
63. Casali P, Schettino EW, (1996) Structure and function of natural antibodies. Curr Top Microbiol Immunol 210: 167-179.
64. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, et al. (1983) Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 309: 453-458.
65. Nagase H, Agematsu K, Kitano K, Takamoto M, Okubo Y, et al. (2001) Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol 100: 250-259.
66. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, et al. (2004) Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180-2186.
67. Abelian A, Burling K, Easterbrook P, Winter G, (2004) Hyperimmunoglobulinemia and rate of HIV type 1 infection progression. AIDS Res Hum Retroviruses 20: 127-128.
68. Tryphonas H, Karpinski K, O'Grady L, Hayward S, (1991) Quantitation of serum immunoglobulins G, M, and A in the rhesus monkey (M. mulatta) using human monospecific antisera in the enzyme-linked immunosorbent assay: developmental aspects. J Med Primatol 20: 58-66.
69. De Milito A, (2004) B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2: 11-21.
70. Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, et al. (2012) Dynamics of Memory B-Cell Populations in Blood, Lymph Nodes, and Bone Marrow during Antiretroviral Therapy and Envelope Boosting in Simian Immunodeficiency Virus SIVmac251-Infected Rhesus Macaques. J Virol 86: 12591-12604.
71. Griffin DO, Rothstein TL, (2012) Human b1 cell frequency: isolation and analysis of human b1 cells. Front Immunol 3: 122.
72. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467: 591-595.
73. Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, et al. (2009) Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis 48: 123-132.
74. Matyas GR, Beck Z, Karasavvas N, Alving CR, (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 1788: 660-665.